Peripheral neuropathy is a major cause of disability worldwide. Diabetes is the most
common cause of neuropathy, accounting for 50% of cases. Over half of people with …

Neurotoxic anticancer drugs, such as platinum-based anticancer drugs, taxanes, vinca
alkaloids, and proteasome/angiogenesis inhibitors are responsible for chemotherapy …

Purpose Over half of all cancer patients receiving taxane-, platinum-, or vinca alkaloid-based
chemotherapy experience chemotherapy-induced peripheral neuropathy (CIPN), which …

Purpose Chemotherapy-induced peripheral neuropathy (CIPN) may persist after treatment
ends and may lead to functional decline and falls. This study compared objective and self …

Introduction Neo/adjuvant therapy for early-stage breast cancer has become increasingly
common in the last few decades; as a consequence, the number of breast cancer survivors …

Bone is richly innervated by nerve growth factor–responsive (NGF-responsive) tropomyosin
receptor kinase A–expressing (TrKa-expressing) sensory nerve fibers, which are required …

There are currently more than 15 million cancer survivors in the United States, and it is
estimated that with improved treatment and early detection, the number of cancer survivors …

Background Chemotherapy‐induced peripheral neuropathy (CIPN) is one of the most
debilitating long‐term side effects in breast cancer survivors. We conducted a randomized …

Background There are inconsistencies in the literature regarding the prevalence and
assessment of chemotherapy-induced peripheral neuropathy (CIPN). This study explored …

Importance Chemotherapy-induced peripheral neuropathy (CIPN) is a debilitating adverse
effect of neurotoxic cancer treatments including taxanes and platinum agents. Limited …